Kara R Vogel1, Erland Arning2, Teodoro Bottiglieri2, K Michael Gibson3. 1. Division of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, 412 E. Spokane Falls Blvd, Spokane, WA, 99204, USA. 2. Kimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, USA. 3. Division of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, 412 E. Spokane Falls Blvd, Spokane, WA, 99204, USA. mike.gibson@wsu.edu.
Abstract
BACKGROUND: The mainstay of therapy for phenylketonuria (PKU) remains dietary protein restriction. Developmental and neurocognitive outcomes for patients, however, remain suboptimal. We tested the hypothesis that mice with PKU receiving protein-restricted diets would reveal disruptions of brain amino acids that shed light on these neurocognitive deficits. METHOD: Phenylalanine hydroxylase-deficient (PKU) mice and parallel controls (both wild-type and heterozygous) were fed custom diets containing 18, 6, and 4 % protein for 3 weeks, after which tissues (brain, liver, sera) were collected for amino acid analysis profiling. RESULTS: Phenylalanine (phe) was increased in all tissues (p < 0.0001) of PKU mice and improved with protein restriction. In sera, decreased tyrosine (p < 0.01) was corrected (defined as not significantly different from the level in control mice receiving 18 % chow) with protein restriction, whereas protein restriction significantly increased many other amino acids. A similar trend for increased amino acid levels with protein restriction was also observed in liver. In brain, the effects of protein restriction on large neutral amino acids (LNAAs) were variable, with some deficit correction (threonine, methionine, glutamine) and no correction of tyrosine under any dietary paradigm. Protein restriction (4 % diet) in PKU mice significantly decreased lysine, arginine, taurine, glutamate, asparagine, and serine which had been comparable to control mice under 18 % protein intake. CONCLUSION: Depletion of taurine, glutamate, and serine in the brain of PKU mice with dietary protein restriction may provide new insight into neurocognitive deficits of PKU.
BACKGROUND: The mainstay of therapy for phenylketonuria (PKU) remains dietary protein restriction. Developmental and neurocognitive outcomes for patients, however, remain suboptimal. We tested the hypothesis that mice with PKU receiving protein-restricted diets would reveal disruptions of brain amino acids that shed light on these neurocognitive deficits. METHOD:Phenylalanine hydroxylase-deficient (PKU) mice and parallel controls (both wild-type and heterozygous) were fed custom diets containing 18, 6, and 4 % protein for 3 weeks, after which tissues (brain, liver, sera) were collected for amino acid analysis profiling. RESULTS:Phenylalanine (phe) was increased in all tissues (p < 0.0001) of PKUmice and improved with protein restriction. In sera, decreased tyrosine (p < 0.01) was corrected (defined as not significantly different from the level in control mice receiving 18 % chow) with protein restriction, whereas protein restriction significantly increased many other amino acids. A similar trend for increased amino acid levels with protein restriction was also observed in liver. In brain, the effects of protein restriction on large neutral amino acids (LNAAs) were variable, with some deficit correction (threonine, methionine, glutamine) and no correction of tyrosine under any dietary paradigm. Protein restriction (4 % diet) in PKUmice significantly decreased lysine, arginine, taurine, glutamate, asparagine, and serine which had been comparable to control mice under 18 % protein intake. CONCLUSION: Depletion of taurine, glutamate, and serine in the brain of PKUmice with dietary protein restriction may provide new insight into neurocognitive deficits of PKU.
Authors: Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson Journal: Mol Genet Metab Date: 2013-08-15 Impact factor: 4.797
Authors: A V Glushakov; O Glushakova; M Varshney; L K Bajpai; C Sumners; P J Laipis; J E Embury; S P Baker; D H Otero; D M Dennis; C N Seubert; A E Martynyuk Journal: Brain Date: 2005-01-05 Impact factor: 13.501
Authors: Kara R Vogel; Garrett R Ainslie; Brian Phillips; Erland Arning; Teodoro Bottiglieri; Danny D Shen; K Michael Gibson Journal: Mol Genet Metab Rep Date: 2015-06-01
Authors: Marta Gonzalez-Freire; Alberto Diaz-Ruiz; David Hauser; Jorge Martinez-Romero; Luigi Ferrucci; Michel Bernier; Rafael de Cabo Journal: Ageing Res Rev Date: 2020-02-25 Impact factor: 10.895
Authors: Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson Journal: Neurochem Int Date: 2019-02-26 Impact factor: 3.921
Authors: Rachna Manek; Yao V Zhang; Patricia Berthelette; Mahmud Hossain; Cathleen S Cornell; Joseph Gans; Gulbenk Anarat-Cappillino; Sarah Geller; Robert Jackson; Dan Yu; Kuldeep Singh; Sue Ryan; Dinesh S Bangari; Ethan Y Xu; Sirkka R M Kyostio-Moore Journal: Sci Rep Date: 2021-11-24 Impact factor: 4.379